Some neurologists and a consumer watchdog worry that an Eli Lilly–affiliated direct-to-consumer telehealth platform for Alzheimer’s could lead to misdiagnosis or unnecessary treatment.

Eli Lilly’s new oral weight loss pill, orforglipron, successfully passed late-stage trials, showing positive results for ...

Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

They expect to submit to the FDA for approval for weight loss before the end of the year, and for diabetes treatment in 2026.

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

Valiltramiprosate was no better than placebo at slowing cognitive decline, as assessed by ADAS-Cog13, in the latest phase 3 ...

The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat some patients with mild cognitive impairment in the early stages of Alzheimer's disease, ending a more than ...

In a detailed feature by TIME Magazine, pharmaceutical giant Eli Lilly has unveiled promising early results from clinical ...